Want to see BNGO full AI Analyst Report?
Top Page
BioNano Genomics
(NASDAQ:BNGO)
Select Model
Select Model
Rating:52Neutral
Price Target:
$1.00
▼(-9.91% Downside)
Action:Reiterated
Date:08/11/26
BNGO’s score is held back primarily by weak financial fundamentals (ongoing losses and negative free cash flow), partially offset by a constructive earnings call (revenue beat, improved margins, and raised guidance) and modestly improving near-term technicals that still sit within a longer-term downtrend. Valuation contributes limited support due to negative earnings and no dividend.
Positive Factors
Gross margin improvement
Sustained gross margin expansion to 53% reflects improved pricing, product mix and cost control, increasing the leverage on incremental revenue. A structurally higher margin base enhances the path to profitability if revenue growth continues and supports reinvestment in R&D and commercialization over months.
Negative Factors
Limited cash runway
With roughly $10.4M in cash and negative TTM operating/free cash flow (~-$20.5M), the company remains dependent on external financing or rapid margin-driven cash inflection. Persistent cash burn creates dilution risk and constrains long‑term strategic investments unless profitability improves.
Read all positive and negative factors
Positive Factors
Negative Factors
Gross margin improvement
Sustained gross margin expansion to 53% reflects improved pricing, product mix and cost control, increasing the leverage on incremental revenue. A structurally higher margin base enhances the path to profitability if revenue growth continues and supports reinvestment in R&D and commercialization over months.
Read all positive factors
BioNano Genomics Key Performance Indicators (KPIs)
Any
Revenue by Segment
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Shows how much revenue each business segment generates, highlighting which areas drive growth and which may need strategic adjustments.
Data provided by:
The Fly
The FlyBioNano Genomics (BNGO) vs. SPDR S&P 500 ETF (SPY)
Market Cap
$13.90M
Dividend YieldN/A
Average Volume (3M)114.16K
Price to Earnings (P/E)―
Beta (1Y)1.55
Revenue Growth10.03%
EPS Growth91.68%
CountryUS
Employees96
SectorHealthcare
Sector Strength45
IndustryMedical - Diagnostics & Research
Share Statistics
EPS (TTM)-3.73
Shares Outstanding11,777,000
10 Day Avg. Volume73,515
30 Day Avg. Volume114,157
Financial Highlights & Ratios
PEG Ratio<0.01
Price to Book (P/B)0.19
Price to Sales (P/S)0.29
P/FCF Ratio-0.51
Enterprise Value/Market Cap<0.01
Enterprise Value/Revenue<0.01
Enterprise Value/Gross Profit<0.01
Enterprise Value/Ebitda>-0.01
Forecast
1Y Price Target
$4.00Price Target Upside260.36% Upside
Rating ConsensusModerate Buy
Number of Analyst Covering1
EPS Forecast (FY)-2.13
Revenue Forecast (FY)$32.14M
BioNano Genomics Business Overview & Revenue Model
Company Description
Bionano Genomics, Inc. focuses on providing advanced solutions for analyzing genomes. The company's flagship offering is Saphyr, a complete system that processes samples to results, enabling the analysis of structural variations in the genome usin...
How the Company Makes Money
BioNano Genomics makes money primarily by selling and supporting its optical genome mapping (OGM) ecosystem. Key revenue streams include: (1) Instrument/system sales: revenue from selling OGM instruments (e.g., Saphyr systems) to laboratories. The...
BioNano Genomics Earnings Call Summary
Earnings Call Date:Aug 10, 2026
(Q2-2026)
| % Change Since: |
Next Earnings Date:Oct 29, 2026
Earnings Call Sentiment Positive
The call conveyed strong execution on key commercial and clinical fronts: double-digit revenue growth, record flow-cell sales, a shift to higher-margin consumable revenue, improved gross margins (53%), significant clinical publications validating OGM, and the retirement of convertible debt. These positives were tempered by operational constraints — notably manufacturing capacity and backorders — a modest cash balance with runway into early 2027, and a YoY decline in software revenue. Management raised the low end of full-year guidance but remained cautious on the upside until supply constraints are resolved.Positive Updates
Revenue Growth and Beat
Total revenue of $8.2 million in Q2 2026, up 21% year-over-year, and above prior guidance of $7.5M–$7.8M.
Negative Updates
Manufacturing Capacity Constraints and Backlog
Consumable demand continues to outpace current manufacturing capacity, creating backorders and limiting management's willingness to raise the upper end of revenue guidance; supply constraints cited as the primary reason for conservative near-term outlook.
Read all updates
Q2-2026 Updates
Positive
Negative
Revenue Growth and Beat
Total revenue of $8.2 million in Q2 2026, up 21% year-over-year, and above prior guidance of $7.5M–$7.8M.
Read all positive updates
Company Guidance
Bionano raised the low end of its full‑year 2026 revenue guidance to $31.0M–$33.0M (up ~9%–16% vs. 2025) and initiated Q3 guidance of $8.2M–$8.6M (up ~11%–16% vs. Q3 2025) after reporting Q2 revenue of $8.2M (up 21% YoY and above prior guidance of $7.5M–$7.8M), selling 9.22k flow cells (up 27% YoY), delivering a record adjusted gross margin of 53%, recording adjusted operating expense of $8.7M, ending the quarter with $10.4M in cash/short‑term securities (including $0.5M restricted) and a cash runway into at least Q1 2027, and noting full retirement of its senior secured convertible debt — while management cautioned they kept the upside conservative due to flow‑cell manufacturing constraints, backlog and several large orders that could slip.BioNano Genomics Financial Statement Overview
Summary
Income Statement
22
Negative
Balance Sheet
58
Neutral
Cash Flow
26
Negative
| Breakdown | TTM | Dec 2025 | Mar 2025 | Dec 2023 | Dec 2022 | Dec 2021 |
|---|---|---|---|---|---|---|
Income Statement | ||||||
| Total Revenue | 30.18M | 28.51M | 30.78M | 36.12M | 27.80M | 17.98M |
| Gross Profit | 14.34M | 6.26M | 380.00K | 9.57M | 5.95M | 3.87M |
| EBITDA | -22.41M | -16.30M | -97.47M | -213.60M | -120.31M | -73.86M |
| Net Income | -32.16M | -26.39M | -112.02M | -232.49M | -132.60M | -72.44M |
Balance Sheet | ||||||
| Total Assets | 47.59M | 73.58M | 76.67M | 214.40M | 307.50M | 377.10M |
| Cash, Cash Equivalents and Short-Term Investments | 9.92M | 13.26M | 9.47M | 66.77M | 113.19M | 250.61M |
| Total Debt | 6.70M | 6.92M | 27.30M | 79.41M | 11.67M | 10.70M |
| Total Liabilities | 15.98M | 29.16M | 41.30M | 118.25M | 58.10M | 39.98M |
| Stockholders Equity | 31.61M | 44.42M | 35.38M | 96.16M | 249.40M | 337.12M |
Cash Flow | ||||||
| Free Cash Flow | -20.48M | -16.34M | -69.03M | -126.87M | -128.12M | -73.39M |
| Operating Cash Flow | -20.48M | -16.34M | -68.92M | -125.18M | -124.82M | -71.93M |
| Investing Cash Flow | 18.48M | -12.75M | 73.84M | 24.16M | 82.77M | -278.06M |
| Financing Cash Flow | 2.64M | 24.04M | -13.69M | 113.81M | 23.01M | 336.11M |
BioNano Genomics Technical Analysis
Neutral
1.11
Price Trends
1.15
Positive
1.18
Negative
1.32
Negative
Market Momentum
<0.01
Negative
57.17
Neutral
93.59
Negative
Evaluating momentum and price trends is crucial in stock analysis to make informed investment decisions. For BNGO, the sentiment is Neutral. The current price of 1.11 is below the 20-day moving average (MA) of 1.12, below the 50-day MA of 1.15, and below the 200-day MA of 1.32, indicating a neutral trend. The MACD of <0.01 indicates Negative momentum. The RSI at 57.17 is Neutral, neither overbought nor oversold. The STOCH value of 93.59 is Negative, not indicating any strong overbought or oversold conditions. Overall, these indicators collectively point to a Neutral sentiment for BNGO.
BioNano Genomics Risk Analysis
BioNano Genomics disclosed 83 risk factors in its most recent earnings report. BioNano Genomics reported the most risks in the "Finance & Corporate" category.
Finance & Corporate - Financial and accounting risks. Risks related to the execution of corporate activity and strategy
Latest Risks Added 0 New Risks
BioNano Genomics Peers Comparison
UnderperformOutperform
Sector (51)
Name | Overall Rating | Market Cap | P/E Ratio | ROE | Dividend Yield | Revenue Growth | EPS Growth |
|---|---|---|---|---|---|---|---|
58 Neutral | $251.01M | -7.57 | -788.19% | ― | 34.46% | 43.48% | |
53 Neutral | $1.54B | -12.88 | -46.47% | ― | -13.26% | 14.26% | |
52 Neutral | $13.90M | -0.32 | -71.38% | ― | 10.03% | 91.68% | |
51 Neutral | $7.86B | -0.30 | -43.30% | 2.27% | 22.53% | -2.21% | |
50 Neutral | $97.71M | -1.06 | -10.96% | ― | -0.21% | 75.40% | |
48 Neutral | $513.16M | -6.58 | -7.87% | ― | 6.83% | -69.59% | |
47 Neutral | $303.21M | -2.54 | -32.59% | ― | -3.16% | 72.02% |
* Healthcare Sector Average
BNGO
BioNano Genomics
1.18
-1.86
-61.18%
MYGN
Myriad Genetics
3.03
-2.68
-46.94%
FLGT
Fulgent Genetics
18.56
-2.70
-12.70%
PSNL
Personalis
14.04
9.44
205.22%
BNR
Burning Rock Biotech
8.83
1.35
18.05%
BDSX
Biodesix
24.00
16.08
203.03%
BioNano Genomics Corporate Events
Business Operations and StrategyExecutive/Board Changes
Bionano Genomics Names Alex Hastie Chief Scientific Officer
Positive
Jun 24, 2026
On June 24, 2026, Bionano Genomics announced the appointment of longtime company scientist Alex Hastie, Ph.D., as chief scientific officer effective July 20, 2026, marking his return after contributing to genomic testing work in oncology. Hastie, ...
Business Operations and StrategyExecutive/Board Changes
BioNano Genomics Announces Resignation of Chief Medical Officer
Negative
Jun 5, 2026
On June 2, 2026, Bionano Genomics, Inc. announced that its Chief Medical Officer, Alka Chaubey, Ph.D., had resigned, with her departure to take effect on July 5, 2026. The exit of the company’s top medical executive may prompt adjustments in...
Business Operations and StrategyFinancial DisclosuresRegulatory Filings and Compliance
BioNano Genomics Retires Secured Debt, Boosts Flexibility
Positive
May 28, 2026
On May 28, 2026, Bionano Genomics, Inc. announced that it had fully retired and cancelled all of its outstanding Senior Secured Convertible Debentures, which had an aggregate face value of $20 million and were originally issued in May 2024. The co...
Executive/Board ChangesShareholder Meetings
BioNano Genomics Stockholders Approve 2026 Annual Meeting Proposals
Neutral
May 14, 2026
On May 14, 2026, Bionano Genomics, Inc. held its 2026 Annual Meeting of Stockholders, with 4,225,995 shares represented, or about 38.1% of shares outstanding and entitled to vote as of the March 19, 2026 record date. Shareholders elected Albert Lu...
Glossary
BuyA stock rated as a "Buy" is expected to perform better than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock is likely to deliver higher returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
HoldA stock rated as a "Hold" is expected to perform in line with the overall market or a specific benchmark. This rating indicates that the stock is neither particularly compelling nor unfavorable for investment. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
SellA stock rated as a "Sell" is expected to perform worse than the overall market or a specific benchmark over the near-to-medium term. This rating suggests the stock may deliver lower returns compared to other stocks in the same sector or market index. Note: This is not investment advice; please consult a financial advisor before making investment decisions.
Disclaimer
This AI Analyst Stock Report is automatically generated by our AI systems using advanced algorithms and publicly available financial, technical, and market data. While the information provided aims to be accurate and insightful, it is intended for informational purposes only and should not be considered financial advice. Any content created by an AI (Artificial Intelligence) system may contain inaccuracies and/or contain errors. Investing in stocks carries inherent risks, and past performance is not indicative of future results. This report does not account for your personal financial circumstances, objectives, or risk tolerance. Always conduct your own research or consult with a qualified financial advisor before making investment decisions. The analysis and recommendations provided are based on historical and current data and may not fully reflect future market conditions or unexpected developments. Neither the creators of this report nor its affiliated entities guarantee the accuracy, completeness, or reliability of the information presented. Use this report at your own discretion and risk.